Answers are grounded in this paper and cite their sources.
Increasing efforts have focused on identifying vulnerabilities within the signaling networks of KRAS that sustain its oncogenic activity. Recently, Furin-like enzymes or proprotein convertase, proteases responsible for the activation of various signaling molecules, have emerged as key regulators. Furin, modulate KRAS-related signaling by processing growth factors, cytokines, and receptor tyrosine kinases (RTKs). Repression of Furin selectively impairs the proliferation and survival of KRAS-mutant colorectal cancer cells compared with wild-type KRAS cells. Furin inhibition disrupts various RTK maturation, attenuates downstream signaling, and remodels the tumour microenvironment toward an immune-stimulatory phenotype. Furin inhibition also repress KRAS-mutant-mediated resistance by blocking the maturation of multiple escape pathways, including compensatory RTK activation. This review summarizes current evidence on the crosstalk between KRAS signaling and Furin-like enzymes, emphasizing their cooperative roles in tumour progression and immune escape. Targeting protein maturation by these enzymes may therefore represent a therapeutic approach for KRAS-mutant colorectal cancer, offering new opportunities for personalized treatment.
No takes yet. Share an insight, caveat, or question.
Siegfried et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: